28340-62-7

Basic information

• Product Name: 4-(dimethylamino)-2-nitrobenzonitrile
• Synonyms: 4-(dimethylamino)-2-nitrobenzonitrile
• CAS NO: 28340-62-7
• Molecular Weight: 191.189
• Mol File: 28340-62-7.mol
• Article Data: 4

Chemical Properties

• CAS DataBase Reference: 4-(dimethylamino)-2-nitrobenzonitrile(CAS DataBase Reference)
• NIST Chemistry Reference: 4-(dimethylamino)-2-nitrobenzonitrile(28340-62-7)
• EPA Substance Registry System: 4-(dimethylamino)-2-nitrobenzonitrile(28340-62-7)

Safety Data

• Hazardous Substances Data: 28340-62-7(Hazardous Substances Data)

Upstream product

• 50817-44-2 N-(4-chloro-3-nitrophenyl)-N,N-dimethylamine 
• 364-78-3 2-nitro-4-fluoroaniline 
• 544-92-3 copper(I) cyanide 
• 364-77-2 4-fluoro-1-iodo-2-nitrobenzene 
• 68-12-2 N,N-dimethyl-formamide 
• 680-31-9 N,N,N,N,N,N-hexamethylphosphoric triamide 
• 345-17-5 1-chloro-4-fluoro-2-nitrobenzene 
• 56670-20-3 2-nitro-4-dimethylaminobenzaldehyde 

Downstream Products

• 113305-55-8 4-dimethylamino-2-nitrobenzamide 
• 28340-63-8 2-amino-4-dimethylamino-benzonitrile 

Relevant articles and documents

Copper-Catalyzed One-Pot Synthesis of Quinazolinones from 2-Nitrobenzaldehydes with Aldehydes: Application toward the Synthesis of Natural Products

A novel, efficient, and atom-economical approach for the construction of quinazolinones from 2-nitrobenzaldehydes has been unveiled via copper-catalyzed nitrile formation, hydrolysis, and reduction in one pot for the first time. In this reaction, urea is used as a source of nitrogen for nitrile formation, hydrazine hydrate is used for both the reduction of the nitro group and the hydrolysis of nitrile, and atmospheric oxygen is used as the sole oxidant. The method portrays a wide substrate scope with good functional group tolerances. Moreover, this method was applied for the synthesis of schizocommunin, tryptanthrin, phaitanthrin-A, phaitanthrin-B, and 8H-quinazolino[4,3-b]quinazolin-8-one.

NOVEL SULFONAMIDE COMPOUNDS

The invention relates to sulfonamide compounds of formula (I), where A, B, R3 and R4 are as defined in the claims, and their use as orexin receptor antagonists in the prevention and treatment of eating and drinking disorders, all types of sleep disorders, all kinds of cognitive dysfunctions in the healthy population and psychiatric and neurologic disorders. Formula (I).